---
title: "CSPC Wins China Approval for Long-Acting Schizophrenia Injection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293749125.md"
description: "CSPC Pharmaceutical Group received marketing approval in mainland China for Paliperidone Palmitate Injection, a long-acting antipsychotic for schizophrenia. This approval expands CSPC's psychiatric portfolio and strengthens its position in the CNS drug market. The product is recommended in clinical guidelines for improving patient adherence. Analysts maintain a 'Buy' rating with a HK$13.05 price target."
datetime: "2026-07-24T11:09:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293749125.md)
  - [en](https://longbridge.com/en/news/293749125.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293749125.md)
generator: "portal-rs"
---

# CSPC Wins China Approval for Long-Acting Schizophrenia Injection

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.

CSPC Pharmaceutical Group has received marketing approval in mainland China for its independently developed Paliperidone Palmitate Injection, a second-generation long-acting antipsychotic indicated for both acute and maintenance treatment of schizophrenia. Available in multiple strengths, the once-monthly injection is designed to deliver rapid onset without supplemental oral medication, improving adherence and reducing relapse and rehospitalisation rates for patients with poor treatment compliance.

The product has been recommended in leading domestic and international clinical guidelines, including the 2025 Chinese Guidelines for the Prevention and Treatment of Schizophrenia, underscoring its clinical and pharmacoeconomic value. This approval expands CSPC’s psychiatric and neurological portfolio and strengthens its strategic position in the central nervous system drug market, as the company signals ongoing investment in high-value therapies to broaden treatment options for patients.

The most recent analyst rating on (HK:1093) stock is a Buy  
 with a HK$13.05 price target.  
 To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock,  
 see the HK:1093 Stock Forecast page. 

**More about CSPC Pharmaceutical Group**

CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company listed on the Stock Exchange of Hong Kong. The group focuses on developing and marketing innovative drugs, with a growing portfolio in psychiatric and neurological therapies aimed at addressing high-burden chronic conditions such as schizophrenia.

**Average Trading Volume:** 100,766,484

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$96.63B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer](https://longbridge.com/en/news/297024431.md)
- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**